AZİTROMİSİN'İN ERİŞKİNDE AĞIR OLMAYAN TOPLUM KÖKENLİ PNÖMONİ TEDAVİSİNDE KULLANIMI: ETKİNLİK VE GÜVENİLİRLİK ARAŞTIRMASI

Anahtar Kelimeler:

toplum kökenli pnömoni, azitromisin, makrolid

Azithromycin in the treatment of adults with mild to moderate community-acquired pneumonia: A study of efficacy and tolerability

Objective: This study was designed to investigate the efficacy and tolerability of azithromycin (500 mg once daily for 3 days) in the treatment of adults with mild to moderate community-acquired pneumonia. Methods: Eleven patients with mild to moderate pneumonia were enrolled in the study. The diagnosis was based on clinical and radiographical findings. The patients were treated with azithromycin and they were assessed for side effects, during one-month-of, follow up. Post treatment evalution was categorized on either a cure, im-provement, failure or relapse. The results were expressed as a percentage of the total number of patients. Results: The efficacy was recorded at the end of treatment as a cure in 10 of 11 patients (91%). Only one patient had relapsed (9%). The rate of treatment-related adverse events was (18%). Conclusion: This study shows that a 3-day, once-daily course of azithromycin is clinically effective and well tolerated in the treatment of mild to moderate community-acquired pneumonia. Furthermore, the patient com-pliance to treatment is improved with such a short regimen.

Keywords:

Community-acquired pneumonia, azithromycin, macrolid,

PDF

___

1. Ekim N. Toplum kökenli pnömonilere klinik ve tanýsal yaklaþým. Uçan ES (ed). Bir devin uyanýþý: Pnömoniler. Ýzmir: Saray Kitabevi Medikal Yayýncýlýk, 1995; 4-22
2. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia:Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26.
3. O’Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17: 828-33
4. Gris P. Once-daily 3-day azithromycin versus a threetimes-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections:results of a randomized, double-bind comparative study. J Antimicrob.Chemother 1996; 37(suppl C): 93-101
5. Balmes P, Clerc G, Dupont B et al. Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1991; 10(5): 437-9.
6. Roord JJ, Wolf BHM, Goossens MMHT, Kimpen JLL. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azitromycin and 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother 1996; 40: 2765-8.
7. Janknegt R, Wijnands WJA, Stobberingk E. Antibiotics in lower respiratory tract infections: Drug selection by means of the system of objectified judgement analysis (SOJA) method. EHP 1996; 2: 64-71.
8. Uzun O, Hayran M, Akova M, Gur D, Akalin H. Efficacy of a three-day course of azithromisin in the treatment of community-acquired pneumococcal pneumonia. Preliminary report. J Chemoter 1994; 6: 53-57.
9. Anzueto A., Gallis H. Clinical evaluation of azithromycin in respiratory tract infections due to bacterial pathogens. Presented at American College of Physicians Annual Session 1994, Miami.
10. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 (suppl A): 73-82
11. Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother 1998; 10: 64-68.
12. Fryters SR. Lower respiratory tract infections: Management of community-acquired bronchitis and pneumonia. Pharmacy Practice 1996; 12 (4): 1-12.
13. Rizzato G, Montemurro L, Fraioli D, Pozzolini R, Magliano E. Efficacy of a three day course of azithromycin in moderately severe community acquired pneumonia. Eur Respir J 1995; 8: 398-402